U.S. markets close in 4 hours 20 minutes
  • S&P 500

    4,558.08
    +45.04 (+1.00%)
     
  • Dow 30

    34,536.50
    +514.46 (+1.51%)
     
  • Nasdaq

    15,292.09
    +38.04 (+0.25%)
     
  • Russell 2000

    2,185.90
    +38.48 (+1.79%)
     
  • Crude Oil

    66.63
    +1.06 (+1.62%)
     
  • Gold

    1,767.60
    -16.70 (-0.94%)
     
  • Silver

    22.40
    +0.06 (+0.27%)
     
  • EUR/USD

    1.1324
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4440
    +0.0100 (+0.70%)
     
  • GBP/USD

    1.3316
    +0.0039 (+0.29%)
     
  • USD/JPY

    112.9820
    +0.2020 (+0.18%)
     
  • BTC-USD

    56,300.47
    -2,467.89 (-4.20%)
     
  • CMC Crypto 200

    1,432.32
    -6.56 (-0.46%)
     
  • FTSE 100

    7,135.44
    -33.24 (-0.46%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

Such Is Life: How ImmunoGen (NASDAQ:IMGN) Shareholders Saw Their Shares Drop 57%

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to perform badly. For example, after five long years the ImmunoGen, Inc. (NASDAQ:IMGN) share price is a whole 57% lower. We certainly feel for shareholders who bought near the top. Furthermore, it's down 21% in about a quarter. That's not much fun for holders. But this could be related to the weak market, which is down 14% in the same period.

Check out our latest analysis for ImmunoGen

Because ImmunoGen made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last five years ImmunoGen saw its revenue shrink by 1.1% per year. While far from catastrophic that is not good. The share price decline of 15% compound, over five years, is understandable given the company is losing money, and revenue is moving in the wrong direction. We don't think anyone is rushing to buy this stock. Not that many investors like to invest in companies that are losing money and not growing revenue.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:IMGN Income Statement May 4th 2020
NasdaqGS:IMGN Income Statement May 4th 2020

ImmunoGen is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

It's good to see that ImmunoGen has rewarded shareholders with a total shareholder return of 14% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 15% per year over five years. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for ImmunoGen you should be aware of.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.